J&J Files 8-K on Operations & Financial Condition, Details Notes Due

TL;DR

**JNJ just dropped an 8-K on its financials, highlighting upcoming debt maturities.**

AI Summary

Johnson & Johnson (JNJ) filed an 8-K on January 23, 2024, to report its results of operations and financial condition. The filing specifically mentions several notes due in 2024, 2028, and 2035, including 0.650% Notes Due 2024, 5.50% Notes Due 2024, 1.150% Notes Due 2028, and 1.650% Notes Due 2035. This matters to investors because it provides an update on the company's financial health and upcoming debt obligations, which can impact future earnings and cash flow.

Why It Matters

This filing provides a snapshot of Johnson & Johnson's financial status and upcoming debt maturities, which is crucial for assessing its liquidity and future financial commitments.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial information and does not indicate any immediate or significant new risks.

Analyst Insight

Investors should note the upcoming debt maturities, particularly the 2024 notes, and consider how their repayment or refinancing might impact Johnson & Johnson's cash flow and financial strategy in the near term.

Key Numbers

• 0.650% — Interest rate (for Notes Due 2024)
• 5.50% — Interest rate (for Notes Due 2024)
• 1.150% — Interest rate (for Notes Due 2028)
• 1.650% — Interest rate (for Notes Due 2035)

Key Players & Entities

• Johnson & Johnson (company) — the registrant filing the 8-K
• 0.650% Notes Due 2024 (dollar_amount) — a specific debt instrument mentioned
• 5.50% Notes Due 2024 (dollar_amount) — a specific debt instrument mentioned
• 1.150% Notes Due 2028 (dollar_amount) — a specific debt instrument mentioned
• 1.650% Notes Due 2035 (dollar_amount) — a specific debt instrument mentioned
• January 23, 2024 (date) — date of the earliest event reported

FAQ

From the Filing

0000200406-24-000004.txt : 20240123 0000200406-24-000004.hdr.sgml : 20240123 20240123074537 ACCESSION NUMBER: 0000200406-24-000004 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 19 CONFORMED PERIOD OF REPORT: 20240123 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240123 DATE AS OF CHANGE: 20240123 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JOHNSON & JOHNSON CENTRAL INDEX KEY: 0000200406 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 221024240 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03215 FILM NUMBER: 24550490 BUSINESS ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 BUSINESS PHONE: 732-524-2455 MAIL ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 8-K 1 jnj-20240123.htm 8-K jnj-20240123 0000200406 false 0000200406 2024-01-23 2024-01-23 0000200406 us-gaap:CommonStockMember 2024-01-23 2024-01-23 0000200406 jnj:A0.650NotesDue2024Member 2024-01-23 2024-01-23 0000200406 jnj:A5.50NotesDue2024Member 2024-01-23 2024-01-23 0000200406 jnj:A1.150NotesDue2028Member 2024-01-23 2024-01-23 0000200406 jnj:A1.650NotesDue2035Member 2024-01-23 2024-01-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of report (Date of earliest event reported):  January 23, 2024 Johnson & Johnson  (Exact name of registrant as specified in its charter)    New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) One Johnson & Johnson Plaza , New Brunswick , New Jersey    08933   (Address of Principal Executive Offices)  (Zip Code)  Registrant's telephone number, including area code: 732 - 524-0400   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐             Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  ☐             Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  ☐             Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17                CFR 240.14d-2(b))  ☐             Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17                CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).     Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, Par Value $1.00 JNJ New York Stock Exchange 0.650% Notes Due May 2024 JNJ24C New York Stock Exchange 5.50% Notes Due Nov